Immune Signatures and Clinical Outcomes in Acute Pancreatitis A Study to Predict Severe Acute Pancreatitis Using Cytokine Testing

What this Trial Is About

Researchers are studying acute pancreatitis AP to develop an early prediction tool for severe acute pancreatitis SAP and to define a unique immune profile that differentiates SAP from moderate acute pancreatitis MAP. This observational study aims to validate a multi-cytokine panel for early SAP prediction and identify specific immune cells linked to cytokine patterns, helping to understand the immune pathways driving SAP development. Participants diagnosed with acute pancreatitis based on the revised Atlanta criteria will provide blood samples and complete surveys and interviews at three time points within 36 hours of hospital arrival, at 48 hours, and on hospital day 7 if admitted. Blood samples will be analyzed using CyTOF laboratory testing to measure cytokine levels and correlate these with disease severity. Samples will be stored and may be used for future research. The study includes data collection from electronic health records over five years and involves multiple academic sites with a centralized biospecimen coordinating center. Participants will undergo serial clinical laboratory testing, complete questionnaires, and provide biospecimens during their hospital stay. Researchers will collect data on hospital stay, medical history, clinical course, and disease severity. The primary outcomes focus on validating a multi-cytokine panel and correlating cytokine signatures over four years. Secondary outcomes include studying circulating immune cells and immune pathways. Participants health records will be accessed for five years post-enrollment, and blood samples will be stored up to 15 years for ongoing and future analysis.

iMmune SignAtures and Clinical outComes in AP